CD274 and non-small cell lung carcinoma: Clinical trials with combined therapies in NSCLC patients with resistance to immunotherapy or chemoimmunotherapy with anti-PD-1 or anti-PD-L1 antibodies have been initiated based on the experience with the use of double blockade of immune checkpoints in the first line of treatment in NSCLC patients [1].